Immuno-Oncology | Specialty

Expert Discusses Phase III Trial of Frontline Pembrolizumab in MSI-H Colorectal Cancer

June 30th 2017

Luis A. Diaz, MD, discusses KEYNOTE-177 and the implications of the FDA approval of pembrolizumab for patients with MSI-H or dMMR CRC or other solid tumors.

Weighing Efficacy and Tolerability for Adjuvant Ipilimumab in Advanced Melanoma

June 30th 2017

Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.

Adjuvant PD-1 Inhibition on Horizon in Melanoma

June 30th 2017

Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.

Weber Says Pembrolizumab/Epacadostat Could Become Frontline Treatment of Choice in Melanoma

June 30th 2017

Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).

Expert Discusses Adjuvant Ipilimumab Regimens in Melanoma

June 29th 2017

Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.

Future of Immunotherapy for GU Malignancies Goes Beyond Oncology Department

June 28th 2017

Costas Lallas, MD, discusses the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.

Dr. Apolo on Side Effects of Cabozantinib Plus Immunotherapy Agents in Bladder Cancer

June 28th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

Dr. Sangro on the Efficacy of Nivolumab in HCC

June 27th 2017

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the efficacy of nivolumab (Opdivo) in patients with hepatocellular carcinoma (HCC).

Dr. Ferris on Pembrolizumab and Nivolumab in Head and Neck Cancer

June 27th 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with head and neck cancer.

Dr. Sartor on the Implications of the Analysis of Sipuleucel-T in Prostate Cancer

June 27th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Dr. Machiels on Challenges and Ongoing Trials in Head and Neck Cancer

June 27th 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses challenges still facing the field of head and neck cancer and ongoing trials with a goal to improve patient outcomes.

Dr. Pinato Discusses Intra-tumor Heterogeneity in Primary and Metastatic HCC

June 26th 2017

David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses an analysis of intra-tumor heterogeneity in primary and metastatic hepatocellular carcinoma (HCC).

Expert Hopes Nivolumab/CRT Combo Will Advance Head and Neck Cancer Care

June 26th 2017

Robert Ferris, MD, PhD, discusses the RTOG 3504 trial, as well as the utility of immunotherapy agents for patients with intermediate and high-risk head and neck squamous cell carcinoma.

Update Sustains Frontline Pembrolizumab Benefit in Urothelial Carcinoma

June 26th 2017

Updated phase II results from the KEYNOTE-052 trial showed that first-line treatment with pembrolizumab (Keytruda) produced a long-lasting response for patients with cisplatin-ineligible advanced urothelial cancer.

Expert Addresses Advances and Challenges With Immunotherapy in RCC

June 26th 2017

Moshe Ornstein, MD, discusses the obstacles physicians are facing with the use of immunotherapy for patients with renal cell carcinoma.

Dr. Lara on Epacadostat Plus Pembrolizumab in RCC

June 23rd 2017

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

Potential Role of Immunotherapy in the Treatment of Patients With Sarcoma

June 23rd 2017

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses the potential role for immunotherapy in the treatment of patients with sarcoma.

Frontline Pembrolizumab Approval Leaves Questions for Later Lines in Bladder Cancer

June 23rd 2017

Jorge Garcia, MD, discusses how the field of bladder cancer has transformed with the FDA approval of pembrolizumab, and how oncologists should choose between 5 checkpoint inhibitors now available for the second-line setting and beyond.

Dr. Jonasch on the Potential of Immunotherapy for Sarcomatoid RCC

June 23rd 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Dr. Machiels on Pembrolizumab in Head and Neck Cancer

June 23rd 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses pembrolizumab (Keytruda) in patients with head and neck cancer.